Mangoceuticals, Inc. MGRX PHARMA
Company Overview
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Why Investors Should Care
Revenue has grown at a 270.9% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $456.02K (-26.0% YoY); net profit $-20.64M.
- Trailing 12 Months Year-on-year growth — revenue -59.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 270.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 270.88% |
| 1 Year: | -59.10% |
Stock Price Performance
| 1 Year: | -75.82% |
| 6 Months: | +18.44% |
| 3 Months: | +13.22% |
| 1 Month: | -16.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 270.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 85.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MGRX Mangoceuticals, Inc. PHARMA | 0.41 | -0.41 | $8.84M | 0.00% | -118.64% | -95.10% | 270.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 100.72K | 141.24K | 245.16K | 214.09K | 163.16K | 133.37K | 109.31K | 168.11K | 84.25K | 67.86K |
| Gross Profit | - | - | - | 57.20K | 87.13K | 144.59K | 147.40K | 69.79K | 82.67K | 62.06K | 89.95K | 50.90K | 29.00K |
| Operating Income | -18.71K | -327.90K | -991.83K | -2.56M | -2.29M | -1.80M | -2.37M | -2.17M | -1.76M | -4.58M | -5.27M | -7.54M | -3.13M |
| Net Income | -19.60K | -310.19K | -994.91K | -2.56M | -2.28M | -1.80M | -2.37M | -2.39M | -2.00M | -4.84M | -5.42M | -7.62M | -3.40M |
| Diluted EPS | - | -0.04 | -0.10 | -0.23 | -0.14 | -1.70 | -1.50 | -1.37 | -1.14 | -1.12 | -0.57 | -0.69 | -0.22 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 8.94K | 731.49K | 615.87K | 456.02K |
| Gross Profit | 4.85K | 431.50K | 379.96K | 250.39K |
| Operating Income | -1.99M | -9.22M | -7.97M | -18.03M |
| Net Income | -2.00M | -9.21M | -8.71M | -20.64M |
| Diluted EPS | -0.19 | -8.58 | -4.80 | -2.17 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.00M | 1.05M | 15.37M | 16.09M |
| Total Equity | -16.72K | 614.03K | 774.75K | 13.95M | 15.20M |
| Cash & Equivalents | - | 682.86K | 739.01K | 58.65K | 1.49M |
| Total Liabilities | - | 389.26K | 276.04K | 1.43M | 890.57K |
| Current Liabilities | - | 260.58K | 211.08K | 1.43M | 890.57K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.35M | -7.00M | -4.86M | -5.85M |
| Investing Cash Flow | -43.10K | -3.52K | 65.00K | - |
| Financing Cash Flow | 2.05M | 7.06M | 4.13M | 7.27M |
| Capital Expenditure | -43.10K | -3.52K | - | - |
| Free Cash Flow | -1.39M | -7.00M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 54.3% | 59.0% | 61.7% | 54.9% |
| Operating Margin % | -22,279.7% | -1,260.3% | -1,294.4% | -3,954.3% |
| Net Margin % | -22,352.1% | -1,259.4% | -1,413.6% | -4,526.8% |
| ROE % | -325.4% | -1,189.1% | -62.4% | -135.8% |
| ROCE % | -268.2% | -1,097.9% | -57.2% | -118.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 1.57% | 338.96K | $161.35K |
| 2 | Xtx Topco Ltd | 0.86% | 186.26K | $88.66K |
| 3 | Geode Capital Management, LLC | 0.72% | 156.24K | $74.37K |
| 4 | Ikarian Capital, LLC | 0.64% | 138.15K | $65.76K |
| 5 | Vanguard Capital Management LLC | 0.57% | 123.04K | $58.57K |
| 6 | Vanguard Fiduciary Trust Co | 0.27% | 57.16K | $27.21K |
| 7 | Boothbay Fund Management, LLC | 0.18% | 38.44K | $18.30K |
| 8 | Northern Trust Corporation | 0.17% | 37.58K | $17.89K |
| 9 | HRT Financial LP | 0.17% | 36.00K | $17.14K |
| 10 | Ackerman Capital Advisors, LLC | 0.16% | 34.50K | $16.42K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MGRX
Mangoceuticals (MGRX) Stock Jumps 138% After Hours On Nuclear Reactor Deal: Here's Why It Is Trending Man - Benzinga
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOaXY2eFBMRTdmWllFb1dwVXRxWDFtZjUzbm54TTdXSnBTOFNydWxlMWFicmlTNGJCTWpFU18wOGZCVTNkZVgtcV9odjVlSk9tLVBUTEZLeUw3ajJIRDZKZWhMNmE4aTB0aGJ3WGpkQjEtaTlxVm9RRXFnMlJNYzQ2SV9SYmthUDJ4TnlvNG…
Nuclea’s planned Moltex deal could add 80 nuclear patents - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNeUlNbU5TelNqVTFWVkxYNFVjVWxpT1RJcXkxaGM3RUxyNjJvZFBOVVNZdGNSaVdRTTRTLTlDVHBtbE9EcFhVZjNxVWJrSndzTTJxOFVfSXZfVU55Zm9JcmVCX3F0YUg0ZmZ3T0tOWnZHOTVaNV9nM0h5QTQwaVRxZV9pcTM2b2VSMVFLU0…
MGRX surges after Nuclea Energy reverse-merger deal reshapes company story | MGRX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT0pybS0zLWVJSjUwU202SnpMSk1WWmMzS3hhTmxqbUwxR0ZuYUlBdDhFcGNQWTNvQ1FONmxObDBrTjVxdVQ1LWwwVjhpQU9MTzVPeUZ1QklZc3lONTEzT0NES3RnQXVibTB5RTRPN0kzMm16RDJ4YWJUVXByR0d6eVJwVm9SMjNISXAwUU…
Thursday's after hours session: top gainers and losers - ChartMill
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOZlZOSUk4dGx4YlpLYV9pSGJlbHBTVzdMS1h2NHBKOHBZRVFDS09Fb2NIN0FialJWaVMxcVhkZGhQbWpvTjN1R1ExcUx3elZuOG1PYWYtcTU1aXBMZmdtNUEzNFJLaG5UUzNiUmR0QndnSVBFRFJoV1lUbHFDUWdsMTBsMDByenFjV3lGck…
Market Movers | Winners: CYCU, GCTK, KSCP | Losers: MGRX, CCB, YYAI - Trefis
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOUkpDMDdfVm4yYjhSQVZLZG1MdTVHR19KRHZqSnJ2MDBKSkJJZ3NFYUJLOGRBQV8tRTZLU3FVVjU3TmdWQjZYSkZLVnhTdE1UMV9QRTQxSTMzQlVJNVFPWFZDVkFST3pTelJQLVFSSXlUR0xXVWRjRlRuZkowQmpJRXhETHVwZDRpNHprUm…
MGRX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9OY1RKUldCZjFWbXdodzdGaml3V21RSEJtek5CSzdBb3NYQ1JtVVI4WlVxRDF4YVJkS2FnWE5VRi1VX1dzUXc?oc=5" target="_blank">MGRX</a> <font color="#6f6f6f">Finviz</font>…
MGRX — Frequently Asked Questions
What is the current share price of Mangoceuticals, Inc. (MGRX)?
As of 2026-09-19 21:16 PDT, Mangoceuticals, Inc. (MGRX) trades at $0.41 on NasdaqCM. Its 52-week range is $0.16 to $2.74.
What is the market capitalisation of MGRX?
Mangoceuticals, Inc. (MGRX) has a market capitalisation of $8.84M on NasdaqCM.
What is the P/E ratio of MGRX?
MGRX trades at a trailing price-to-earnings (P/E) ratio of -0.41. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.68.
What is the return on equity (ROE) of MGRX?
MGRX has a return on equity (ROE) of -95.10%. Its return on capital employed (ROCE) is -118.64%.
Is MGRX a good stock to buy?
This page provides a data-driven analysis of Mangoceuticals, Inc. (MGRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.